425 related articles for article (PubMed ID: 31370988)
1. Court personnel attitudes towards medication-assisted treatment: A state-wide survey.
Andraka-Christou B; Gabriel M; Madeira J; Silverman RD
J Subst Abuse Treat; 2019 Sep; 104():72-82. PubMed ID: 31370988
[TBL] [Abstract][Full Text] [Related]
2. Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff.
Andraka-Christou B; Atkins D
Am J Drug Alcohol Abuse; 2020 Nov; 46(6):749-760. PubMed ID: 32969757
[TBL] [Abstract][Full Text] [Related]
3. Online Medication Assisted Treatment Education for Court Professionals: Need, Opportunities and Challenges.
Matusow H; Rosenblum A; Fong C
Subst Use Misuse; 2021; 56(10):1439-1447. PubMed ID: 34154519
[TBL] [Abstract][Full Text] [Related]
4. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions.
Friedmann PD; Hoskinson R; Gordon M; Schwartz R; Kinlock T; Knight K; Flynn PM; Welsh WN; Stein LA; Sacks S; O'Connell DJ; Knudsen HK; Shafer MS; Hall E; Frisman LK;
Subst Abus; 2012; 33(1):9-18. PubMed ID: 22263709
[TBL] [Abstract][Full Text] [Related]
5. Attitudes toward and training in medications for opioid use disorders: a descriptive analysis among employees in the youth legal system and community mental health centers.
O'Reilly LM; Schwartz K; Brown SA; Dir A; Gillenwater L; Adams Z; Zapolski T; Hulvershorn LA; Aalsma M
Subst Abuse Treat Prev Policy; 2024 Jun; 19(1):32. PubMed ID: 38907286
[TBL] [Abstract][Full Text] [Related]
6. Receipt of training about medication for opioid use disorder from pharmaceutical manufacturers: A preliminary study of Florida criminal problem-solving and dependency court staff.
Andraka-Christou B; Atkins D; Madeira J; Silverman RD
Drug Alcohol Rev; 2020 Jul; 39(5):583-587. PubMed ID: 32394525
[TBL] [Abstract][Full Text] [Related]
7. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
8. Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification.
Uebelacker LA; Bailey G; Herman D; Anderson B; Stein M
J Subst Abuse Treat; 2016 Jul; 66():48-53. PubMed ID: 27211996
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Treatments for Opioid Use Disorder.
Fairley M; Humphreys K; Joyce VR; Bounthavong M; Trafton J; Combs A; Oliva EM; Goldhaber-Fiebert JD; Asch SM; Brandeau ML; Owens DK
JAMA Psychiatry; 2021 Jul; 78(7):767-777. PubMed ID: 33787832
[TBL] [Abstract][Full Text] [Related]
10. Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes.
Matusow H; Dickman SL; Rich JD; Fong C; Dumont DM; Hardin C; Marlowe D; Rosenblum A
J Subst Abuse Treat; 2013; 44(5):473-80. PubMed ID: 23217610
[TBL] [Abstract][Full Text] [Related]
11. Criminal problem-solving and civil dependency court policies regarding medications for opioid use disorder.
Andraka-Christou B; Clark MH; Atkins DN; Del Pozo B
Subst Abus; 2022; 43(1):425-432. PubMed ID: 34236297
[No Abstract] [Full Text] [Related]
12. Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: Perspectives from clinicians.
Booty MD; Harp K; Batty E; Knudsen HK; Staton M; Oser CB
J Subst Use Addict Treat; 2023 Jun; 149():209051. PubMed ID: 37084815
[TBL] [Abstract][Full Text] [Related]
13. Assessing the impact of drug courts on provider-directed marketing efforts by manufactures of medications for the treatment of opioid use disorder.
Andraka-Christou B; Nguyen T; Bradford DW; Simon K
J Subst Abuse Treat; 2020 Mar; 110():49-58. PubMed ID: 31952628
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy for opioid addiction in community corrections.
Schwartz RP; Mitchell MM; O'Grady KE; Kelly SM; Gryczynski J; Mitchell SG; Gordon MS; Jaffe JH
Int Rev Psychiatry; 2018 Oct; 30(5):117-135. PubMed ID: 30522370
[TBL] [Abstract][Full Text] [Related]
15. PROTOCOL: Opioid-specific medication-assisted therapy and its impact on criminal justice and overdose outcomes.
Strange CC; Manchak SM; Hyatt JM; Haberman C; Desai A
Campbell Syst Rev; 2021 Mar; 17(1):e1138. PubMed ID: 37050968
[TBL] [Abstract][Full Text] [Related]
16. Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder.
Randall-Kosich O; Andraka-Christou B; Totaram R; Alamo J; Nadig M
J Addict Med; 2020; 14(4):e44-e52. PubMed ID: 31651562
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review.
Moore KE; Roberts W; Reid HH; Smith KMZ; Oberleitner LMS; McKee SA
J Subst Abuse Treat; 2019 Apr; 99():32-43. PubMed ID: 30797392
[TBL] [Abstract][Full Text] [Related]
18. Criminal Justice Professionals' Attitudes Toward Mental Illness and Substance Use.
Lowder EM; Ray BR; Gruenewald JA
Community Ment Health J; 2019 Apr; 55(3):428-439. PubMed ID: 30706306
[TBL] [Abstract][Full Text] [Related]
19. Criminal justice continuum for opioid users at risk of overdose.
Brinkley-Rubinstein L; Zaller N; Martino S; Cloud DH; McCauley E; Heise A; Seal D
Addict Behav; 2018 Nov; 86():104-110. PubMed ID: 29544869
[TBL] [Abstract][Full Text] [Related]
20. Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review.
Maglione MA; Raaen L; Chen C; Azhar G; Shahidinia N; Shen M; Maksabedian E; Shanman RM; Newberry S; Hempel S
J Subst Abuse Treat; 2018 Jun; 89():28-51. PubMed ID: 29706172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
